Active — Not RecruitingNot Applicable

Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients

Italy, Spain204 participantsStarted 2024-03-01

Plain-language summary

Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a population of hematology patients with humoral immunity deficiency.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of B cell malignancies or previous treatment with B cell targeting therapies. * Diagnosis of proven SARS-CoV-2 infection confirmed by a PCR test (only the first infection during the study period will be considered, re-infection will be counted as a secondary endpoint). * Provision of signed and dated informed consent. Exclusion Criteria: * None

What they're measuring

Prevalence of persisting SARS-CoV-2 infection among immunocompromised patients

Timeframe: Retrospective recruitment period will span from January 1st, 2022 to to the date of authorisation by hospital directorates following the Ethics Committees' approvals

Trial details

NCT IDNCT06576102

SponsorMaddalena Giannella

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09-30

View on ClinicalTrials.gov More Persistent COVID-19 trials